PTPA and neoplasm: Recent studies have shown that PP2A inhibits numerous growth and survival pathways, suggesting that the ability to activate PP2A in cancer may suppress the development of resistance, providing greater efficacy in reducing tumor burden when combined with impediments specific to pro-proliferative pathways [2].